sapropterin dihydrochloride
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonurias
Conditions
Phenylketonurias
Trial Timeline
Dec 1, 2004 → Nov 1, 2005
NCT ID
NCT00104260About sapropterin dihydrochloride
sapropterin dihydrochloride is a phase 2 stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT00104260. Target conditions include Phenylketonurias.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00484991 | Pre-clinical | Completed |
| NCT01274026 | Pre-clinical | Completed |
| NCT01141595 | Pre-clinical | Completed |
| NCT00838435 | Phase 3 | Completed |
| NCT00445978 | Phase 2 | Completed |
| NCT00403494 | Phase 2 | Completed |
| NCT00332189 | Phase 3 | Completed |
| NCT00225615 | Phase 3 | Completed |
| NCT00104260 | Phase 2 | Completed |
Competing Products
7 competing products in Phenylketonurias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 74 |
| sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | BioMarin Pharmaceutical | Phase 3 | 74 |
| Pegvaliase-Pqpz | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Palynziq | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin Dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |